Kröger, N M
Deeg, J H
Olavarria, E
Niederwieser, D
Bacigalupo, A
Barbui, T
Rambaldi, A
Mesa, R
Tefferi, A
Griesshammer, M
Gupta, V
Harrison, C
Alchalby, H
Vannucchi, A M
Cervantes, F
Robin, M
Ditschkowski, M
Fauble, V
McLornan, D
Ballen, K
Popat, U R
Passamonti, F
Rondelli, D
Barosi, G
Article History
Received: 25 June 2015
Accepted: 10 August 2015
First Online: 21 August 2015
Competing interests
: NMK declares speakers’ bureau and research funding from Sanofi and Novartis; FC declares consulting and speakers’ bureau from Novartis, AOP and Baxter; DM declares honoraria, speakers’ bureau and research funding from Novartis; AR declares consulting from Piere Fabre Pharma, and Travels from Piere Fabre Pharma and Novartis; EO declares travel expenses for Novartis, Bristol Meyers Squibb and Sanofi; CH declares honoraria and speakers’ bureau from Novartis, Sanofi and Shire. GB declares consulting from Celgene; DN declares speakers’ bureau and travels from Novartis; TB declares consulting, speakers’ bureau from Novartis and Shire; RM declares honoraria and consulting from Novartis, and funding from Incyte, Gilead, Genentech; VG declares honoraria, consulting, and research funding from Novartis and Incyte; AMV declares consulting and speakers’ bureau from Novartis; MD declares consulting from MSD Sharp and Dohme, and research funding from Biosciences; URP declares research funding from CTI Pharma and Otsuka; DR declares consulting from Incyte, and speakers’ bureau from Sanofi. The remaining authors declare no conflict of interest.